RBC Capital Reiterates Outperform on Nuvation Bio, Raises Price Target to $10

Benzinga · 01/07 15:11
RBC Capital analyst Gregory Renza reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $6 to $10.